Charles Schwab’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.5M | Buy |
101,575
+51,276
| +102% | +$2.66M | ﹤0.01% | 2350 |
|
|
2026
Q1 | $2.42M | Sell |
50,299
-13,231
| -21% | -$586K | ﹤0.01% | 2661 |
|
|
2025
Q4 | $2.62M | Sell |
63,530
-1,582
| -2% | -$63.5K | ﹤0.01% | 2683 |
|
|
2025
Q3 | $2.53M | Sell |
65,112
-5,203
| -7% | -$169K | ﹤0.01% | 2689 |
|
|
2025
Q2 | $1.95M | Sell |
70,315
-94,057
| -57% | -$2.39M | ﹤0.01% | 2678 |
|
|
2025
Q1 | $3.65M | Buy |
164,372
+42,353
| +35% | +$872K | ﹤0.01% | 2403 |
|
|
2024
Q4 | $2.41M | Buy |
122,019
+32,393
| +36% | +$739K | ﹤0.01% | 2618 |
|
|
2024
Q3 | $2.24M | Sell |
89,626
-2,782
| -3% | -$67.8K | ﹤0.01% | 2675 |
|
|
2024
Q2 | $1.73M | Buy |
92,408
+8,253
| +10% | +$155K | ﹤0.01% | 2750 |
|
|
2024
Q1 | $1.66M | Sell |
84,155
-72,586
| -46% | -$1.42M | ﹤0.01% | 2650 |
|
|
2023
Q4 | $2.75M | Sell |
156,741
-50,242
| -24% | -$826K | ﹤0.01% | 2521 |
|
|
2023
Q3 | $3.6M | Sell |
206,983
-12,104
| -6% | -$204K | ﹤0.01% | 2407 |
|
|
2023
Q2 | $3.08M | Buy |
219,087
+1,200
| +0.6% | +$16.1K | ﹤0.01% | 2416 |
|
|
2023
Q1 | $2.34M | Buy |
217,887
+12,330
| +6% | +$162K | ﹤0.01% | 2482 |
|
|
2022
Q4 | $3.08M | Buy |
205,557
+1,057
| +0.5% | +$15.4K | ﹤0.01% | 2428 |
|
|
2022
Q3 | $2.63M | Buy |
204,500
+120,997
| +145% | +$1.38M | ﹤0.01% | 2503 |
|
|
2022
Q2 | $810K | Buy |
83,503
+6,421
| +8% | +$59.9K | ﹤0.01% | 2873 |
|
|
2022
Q1 | $767K | Buy |
77,082
+626
| +0.8% | +$6.63K | ﹤0.01% | 2957 |
|
|
2021
Q4 | $900K | Buy |
76,456
+2,286
| +3% | +$28.1K | ﹤0.01% | 2955 |
|
|
2021
Q3 | $845K | Buy |
74,170
+3,874
| +6% | +$50.5K | ﹤0.01% | 2930 |
|
|
2021
Q2 | $980K | Buy |
70,296
+4,850
| +7% | +$73.7K | ﹤0.01% | 2940 |
|
|
2021
Q1 | $1.21M | Sell |
65,446
-369
| -0.6% | -$7.55K | ﹤0.01% | 2792 |
|
|
2020
Q4 | $1.16M | Sell |
65,815
-106
| -0.2% | -$1.86K | ﹤0.01% | 2725 |
|
|
2020
Q3 | $1.01M | Buy |
65,921
+18,874
| +40% | +$354K | ﹤0.01% | 2673 |
|
|
2020
Q2 | $1.2M | Buy |
47,047
+11,551
| +33% | +$241K | ﹤0.01% | 2575 |
|
|
2020
Q1 | $550K | Buy |
35,496
+5,056
| +17% | +$79.1K | ﹤0.01% | 2679 |
|
|
2019
Q4 | $337K | Sell |
30,440
-5,964
| -16% | -$51.8K | ﹤0.01% | 2948 |
|
|
2019
Q3 | $310K | Buy |
36,404
+391
| +1% | +$4.32K | ﹤0.01% | 2962 |
|
|
2019
Q2 | $488K | Buy |
36,013
+12,021
| +50% | +$187K | ﹤0.01% | 2822 |
|
|
2019
Q1 | $434K | Buy |
23,992
+9,092
| +61% | +$176K | ﹤0.01% | 2816 |
|
|
2018
Q4 | $419K | Hold |
14,900
| – | – | ﹤0.01% | 2829 |
|
|
2018
Q3 | $380K | Buy |
+14,900
| New | +$290K | ﹤0.01% | 2930 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
SSC
Charles Schwab's KNSA Position: Q2 2026 in Review
Charles Schwab increased its Kiniksa Pharmaceuticals (KNSA) stake by 102% in Q2 2026, buying an estimated $2.66M and bringing the position to 101,575 shares worth $6.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2350.
Charles Schwab first reported a position in KNSA in Q3 2018 and has held it in 32 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.
- Charles Schwab held 101,575 shares of Kiniksa Pharmaceuticals worth $6.5M as of Q2 2026.
- Charles Schwab bought 51,276 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $2.66M.
- Kiniksa Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2350 holding.
- Charles Schwab first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.